Document Detail


Molecular prediction of progression in patients with conservatively managed prostate cancer.
MedLine Citation:
PMID:  11711356     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To report our results with the use of reverse transcriptase-polymerase chain reaction (RT-PCR) as a potential predictor of prostate cancer (CaP) progression in patients managed with watchful waiting. There has been much recent debate about the safety of treating older patients with localized CaP with watchful waiting. The RT-PCR is an assay that can detect small numbers of prostate cells in circulating blood. METHODS: Blood samples were taken from male and female control patients and from patients with advanced, hormone-treated and untreated localized (watchful-waiting) CaP. Sensitive nested RT-PCR assays were carried out on these samples using primers for both prostate-specific antigen (PSA) and prostate-specific membrane antigen mRNA. RESULTS: Fifty-one blood samples were taken from patients managed with watchful waiting. Fourteen of these had positive RT-PCR results. These patients had a significantly higher PSA velocity than did the patients with negative RT-PCR results. Circulating prostate cells were detected in 18 of 24 patients with advanced CaP, 2 of 34 patients with stable, hormone-treated CaP, and in none of the negative controls. The assay was able to detect 20 LNCaP cells reliably when added to a 5-mL volunteer blood sample. CONCLUSIONS: A significant minority (27%) of patients with untreated localized CaP had detectable circulating prostate cells, and these patients tended to have a progressively rising serum PSA level. Despite low-grade disease and sometimes low serum PSA values, these patients may be at risk of early metastatic progression. RT-PCR, in conjunction with existing prognostic tests, may be of use in predicting which "watchful-waiting" patients are at risk of early progression.
Authors:
I G McIntyre; R B Clarke; E Anderson; N W Clarke; N J George
Related Documents :
7786656 - Comparison of five cardiac markers in the detection of reperfusion after thrombolysis i...
12522696 - The benefits of carotid endarterectomy in the octogenarian: a challenge to the results ...
10463986 - Chromogranin a, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole ac...
20826266 - Comparison of rotational with conventional coronary angiography.
20089016 - Is there any relationship between imatinib mesylate medication and hypothalamic-pituita...
8880246 - Right ventricular myocardial function in arf patients. peep as a challenge for the righ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Urology     Volume:  58     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-11-16     Completed Date:  2001-12-13     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  762-6     Citation Subset:  IM    
Affiliation:
Department of Urology, University Hospital of South Manchester, Withington Hospital, Manchester, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Case-Control Studies
Disease Progression
Humans
Male
Neoplastic Cells, Circulating* / pathology
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood*,  pathology
Reverse Transcriptase Polymerase Chain Reaction*
Sensitivity and Specificity
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men wi...
Next Document:  Early evolution of bladder emptying after myelomeningocele closure.